Aprecap 150mg Injection (Aprepitant)

Description

Aprecap 150mg Injection (Aprepitant) — Complete Clinical and Patient Information Guide

Product Overview

Aprecap 150mg Injection (Aprepitant) contains Fosaprepitant Dimeglumine 150mg IV (fosaprepitant prodrug) as its active pharmaceutical ingredient, belonging to the neurokinin-1 (NK1) receptor antagonist — component of triple antiemetic regimen for highly emetogenic chemotherapy. It is clinically indicated for prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy (HEC — cisplatin-based, anthracycline+cyclophosphamide, carboplatin AUC≥4) as part of triple therapy with 5-HT3 antagonist + dexamethasone. This guide is prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines.

Aprecap is the Sun Pharma brand fosaprepitant (IV prodrug of aprepitant) — the critical add-on to 5-HT3 + dexamethasone for comprehensive acute and delayed CINV prevention with highly emetogenic chemotherapy.

Mechanism of Action

Aprepitant is a highly selective, orally bioavailable neurokinin-1 (NK1) receptor antagonist that targets a distinct pathway in the emetogenic cascade from 5-HT3 antagonists, providing complementary coverage. Substance P — an undecapeptide neurokinin — binds NK1 receptors in the nucleus tractus solitarius, area postrema, and dorsal vagal complex of the brainstem vomiting centre, mediating delayed CINV (the nausea and vomiting occurring 24 hours to 5 days after chemotherapy, which 5-HT3 antagonists partially cover). Aprepitant’s NK1 receptor blockade suppresses both acute and delayed emesis pathways. The standard aprepitant regimen — 125mg on day 1 (or 150mg IV fosaprepitant), then 80mg on days 2 and 3 — combined with a 5-HT3 antagonist and dexamethasone constitutes the triple antiemetic regimen recommended in MASCC/ASCO guidelines for highly emetogenic chemotherapy (cisplatin, carboplatin AUC≥4, cyclophosphamide >1500mg/m², and anthracycline+cyclophosphamide combinations).

Clinical Indications

Aprecap 150mg Injection (Aprepitant) is clinically indicated for prevention of acute and delayed nausea and vomiting associated with highly emetogenic chemotherapy (HEC — cisplatin-based, anthracycline+cyclophosphamide, carboplatin AUC≥4) as part of triple therapy with 5-HT3 antagonist + dexamethasone. All pharmacotherapy for the conditions in this batch should be initiated under qualified medical supervision — self-diagnosis and self-treatment of neurological, psychiatric, and infectious conditions can be dangerous and may delay appropriate care.

Dosage and Administration

Fosaprepitant 150mg IV single dose (day 1 only) on day of chemotherapy as prodrug equivalent replacing 3-day oral aprepitant regimen. Infuse over 20–30 minutes before chemotherapy. Combined with 5-HT3 antagonist and dexamethasone. Aprecap is the Sun Pharma brand aprepitant.

Contraindications

Hypersensitivity to aprepitant. Concurrent pimozide or cisapride — contraindicated (CYP3A4 inhibition increases levels causing QTc prolongation). Severe hepatic impairment.

Drug Interactions

CYP3A4 inhibitor: aprepitant moderately inhibits CYP3A4 — increases levels of dexamethasone (standard triple regimen: reduce dexamethasone dose by 50%), benzodiazepines (midazolam, triazolam, alprazolam), tacrolimus, itraconazole, warfarin (reduce INR with PT monitoring). CYP3A4/CYP2C9 inducer (moderate): may reduce levels of warfarin and hormonal contraceptives — use additional contraception.

A comprehensive medication review before starting any new drug is essential. Neurological and psychiatric medications have numerous clinically important interactions — inform all healthcare providers of your complete medication list.

Adverse Effects

Common: fatigue, hiccups, constipation, diarrhoea, headache, elevated ALT. Hypersensitivity reactions (IV fosaprepitant particularly). Dizziness.

Special Population Considerations

HORMONAL CONTRACEPTIVE INTERACTION: Aprepitant induces CYP3A4 and potentially reduces hormonal contraceptive efficacy — recommend additional non-hormonal contraception during the 3-day course and for 1 month after. DEXAMETHASONE DOSE REDUCTION: When aprepitant is added to a 5-HT3 + dexamethasone regimen, the dexamethasone dose must be halved (from 20mg to 10mg on day 1; 8mg daily days 2–4) to account for aprepitant’s CYP3A4-mediated reduction in dexamethasone clearance.

Storage

Store Aprecap 150mg Injection at room temperature (15–25°C) away from direct sunlight, moisture, and heat. Keep in original packaging out of reach of children and pets. Do not use beyond the expiry date.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless it is nearly time for the next dose. Never double-dose. Do not stop antiepileptic medications abruptly without medical guidance.

Q: Why are three drugs needed to prevent chemotherapy sickness?
A: The three-drug combination (5-HT3 antagonist + NK1 antagonist + dexamethasone) targets three distinct pathways in chemotherapy-induced vomiting. 5-HT3 antagonists block serotonin-mediated acute emesis (0–24 hours). NK1 antagonists block substance P-mediated delayed emesis (24–120 hours — when 5-HT3 blockade alone is insufficient). Dexamethasone enhances both via anti-inflammatory and serotonin/substance P modulating mechanisms. Clinical trials demonstrate this triple regimen controls acute emesis in >95% and delayed emesis in >70% of patients receiving highly emetogenic chemotherapy.

Evidence Base and Clinical Guidelines

The active ingredient in Aprecap 150mg Injection is supported by randomised controlled trial evidence and incorporated into major international clinical guidelines including those from the European Federation of Neurological Societies (EFNS), International Headache Society (IHS), American Academy of Neurology (AAN), WHO, MASCC, and relevant national specialist bodies. GMP-compliant manufacturing ensures consistent product quality, identity, and strength across all batches.

Disease Management and Lifestyle Context

Pharmacological therapy delivers best outcomes when integrated with appropriate lifestyle measures, patient education, and regular clinical review. For migraine: identifying and avoiding personal triggers (stress, sleep disruption, dietary factors), maintaining sleep regularity, and managing anxiety/depression significantly reduce attack frequency alongside preventive pharmacotherapy. For epilepsy: medication adherence, sleep regularity, alcohol avoidance, and seizure first-aid education for caregivers are essential components. For malaria: vector avoidance (bed nets, repellents, protective clothing), travel prophylaxis where indicated, and prompt treatment of fever in endemic areas are critical public health measures. For autoimmune conditions: joint protection strategies, physiotherapy, and monitoring for disease complications complement pharmacotherapy.

Patient Counselling Key Points

• Never stop antiepileptic drugs (AEDs) abruptly — abrupt AED withdrawal can precipitate status epilepticus, a life-threatening medical emergency. Any dose reduction or discontinuation requires gradual tapering under neurologist supervision over weeks to months.
• Driving restrictions: Patients with epilepsy must follow national regulations regarding driving — typically a seizure-free period of 6–12 months required. Medications causing sedation (amitriptyline, some antiemetics, antiepileptics) may impair driving ability — seek advice before driving.
• Pregnancy planning: Multiple drugs in this batch have teratogenic risks (divalproex — highest risk; carbamazepine; topiramate; amitriptyline). Women of childbearing age should discuss contraception and pregnancy planning with their specialist before starting these medications.

Neurological and Psychiatric Disease Context

Migraine affects approximately 1 billion people worldwide — making it the second most disabling neurological condition globally (after stroke) by disability-adjusted life-years (DALYs). Despite its prevalence, migraine remains significantly under-diagnosed and undertreated. The burden of migraine extends far beyond the attack itself — between attacks, anticipatory anxiety, activity avoidance, and the impact on employment, relationships, and quality of life are substantial. Effective migraine management requires a comprehensive approach: accurate diagnosis, acute attack management with triptans or NSAIDs, identification and avoidance of personal triggers, and preventive pharmacotherapy when attacks occur ≥4 days/month or are particularly disabling.

Epilepsy affects approximately 50 million people globally — a lifelong condition requiring adherence to antiepileptic drugs (AEDs) that may be lifelong. Modern antiepileptic pharmacology has expanded dramatically over the past three decades — from phenobarbitone, phenytoin, and carbamazepine, to the introduction of valproate, lamotrigine, topiramate, oxcarbazepine, levetiracetam, and multiple newer agents. The goal of epilepsy management is complete seizure freedom with minimum drug toxicity — 70% of patients achieve seizure freedom on AEDs, allowing many to eventually withdraw medication after prolonged seizure-free periods.

Malaria remains a major global public health emergency — the WHO estimates 247 million malaria cases and 619,000 malaria deaths annually, predominantly in sub-Saharan Africa. The discovery that artemisinin-based combination therapies (ACTs) dramatically outperform previous treatments has been transformative — ACT implementation has saved millions of lives. However, emerging partial artemisinin resistance in Southeast Asia represents an increasing threat to global malaria control.

Nausea and Vomiting Management Context

Nausea and vomiting are among the most disabling symptoms in oncology patients — impacting quality of life, nutritional status, hydration, and treatment adherence. Despite advances in antiemetic pharmacology (5-HT3 antagonists, NK1 antagonists, dexamethasone), chemotherapy-induced nausea and vomiting (CINV) remains incompletely controlled — particularly delayed CINV (>24 hours post-chemotherapy). The triple antiemetic regimen (5-HT3 + NK1 + dexamethasone) represents the current gold standard for highly emetogenic chemotherapy, achieving complete emesis control in 70–80% of patients during the acute phase and 60–70% during the delayed phase.

Evidence Base and Quality Standards

The active ingredients in this product range have been evaluated in landmark randomised controlled trials and systematic reviews, supported by major international guidelines including those from the International Headache Society (IHS), European Federation of Neurological Societies (EFNS), WHO, MASCC/ASCO antiemetic guidelines, and national specialist bodies. GMP-compliant manufacturing ensures consistent product quality, identity, and safety across all batches.

Patient Safety and Medication Adherence

Adherence to neurological medications — antiepileptics, migraine preventives, antimalarials, and antidepressants — is critical for optimal outcomes. For antiepileptic drugs, even a single missed dose can trigger breakthrough seizures with potentially catastrophic consequences (status epilepticus, injury, drowning). For migraine preventives (valproate, topiramate, flunarizine, amitriptyline), consistent daily dosing for at least 3 months is required before efficacy can be assessed — premature discontinuation due to early side effects or perceived lack of benefit is a major cause of preventive therapy failure. For antimalarial treatment, completing the full prescribed course is essential — incomplete treatment leads to treatment failure, recrudescence, and contributes to drug resistance development.

Polypharmacy risks are particularly significant in neurological and psychiatric patients — drug-drug interactions in this population can cause dangerous outcomes: carbamazepine reducing oral contraceptive efficacy (unintended pregnancy); valproate dramatically increasing lamotrigine levels (toxicity); MAO inhibitor interactions with triptans, SSRIs, or amitriptyline (serotonin syndrome); QTc prolongation with combinations of thioridazine, antifungals, or fluoroquinolone antibiotics. A comprehensive medication review before any new prescription in these patients is not optional — it is a clinical safety imperative.

Special Populations Requiring Additional Attention

Elderly patients receiving antiemetics, antiepileptics, and psychiatric medications face heightened risks: metoclopramide extrapyramidal reactions are more common and severe in the elderly; amitriptyline’s anticholinergic effects (confusion, urinary retention, falls) place elderly patients at unacceptable risk; benzodiazepine-amitriptyline combinations can cause respiratory depression and falls. For women of childbearing age: valproate/divalproex, topiramate, and carbamazepine all carry teratogenicity risks requiring counselling and contraception planning before and during therapy. Pregnancy requires specialist review of all neurological, psychiatric, and antimalarial medications — the benefit-risk calculus changes dramatically when foetal wellbeing is considered alongside maternal health management.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed pharmacological and clinical literature, and established guidelines. It does not replace professional medical advice, diagnosis, or treatment from a qualified neurologist, psychiatrist, infectious disease specialist, rheumatologist, or pharmacist. Self-diagnosis and self-treatment of neurological, psychiatric, infectious, and autoimmune conditions can be dangerous and life-threatening. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.